Search

In Stock

Buy Zejula (niraparib) Online

DISEASE INDICATIONS: Gynaecological Cancer

MANUFACTURER: Tesaro UK Limited

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Therapeutic Goods Administration (TGA)

Zejula is primarily indicated for the treatment of ovarian cancer and, in some cases, breast cancer.

From $4,886.66

Clear
Compare

Introduction

In the relentless battle against cancer, medical science has continually strived to develop innovative treatments that can extend and improve the lives of patients. Zejula, known by its generic name Niraparib, is one such groundbreaking medication that has emerged as a beacon of hope in the realm of cancer therapy. Developed by pharmaceutical company Tesaro (now part of GlaxoSmithKline), Zejula belongs to a class of drugs known as poly ADP-ribose polymerase (PARP) inhibitors. This description will delve into the intricacies of Zejula, exploring its mechanism of action, approved indications, potential side effects, and its impact on cancer patients.

Mechanism of Action

To understand the significance of Zejula, it is vital to comprehend its mechanism of action. PARP inhibitors are a class of drugs that target specific proteins within cancer cells. Zejula, in particular, works by inhibiting the activity of PARP enzymes. PARP enzymes play a crucial role in repairing damaged DNA within cells. Cancer cells often have defects in their DNA repair mechanisms, which makes them vulnerable to further DNA damage.

When Zejula is administered, it interferes with the function of PARP enzymes, preventing them from repairing DNA effectively. This leads to a buildup of DNA damage in cancer cells, ultimately causing them to die. This selective targeting of cancer cells while sparing healthy cells is what makes Zejula an invaluable tool in the fight against cancer.

Approved Indications

Zejula has been approved by regulatory agencies in various countries, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of specific cancer types. As of my last knowledge update in September 2021, Zejula was indicated for the following conditions:

  1. Ovarian Cancer: Zejula was approved as a maintenance treatment for women with recurrent ovarian cancer. Specifically, it is indicated for patients with high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved complete or partial response to platinum-based chemotherapy. This means that Zejula can be used to help prevent the recurrence of cancer in these patients.
  2. Advanced Ovarian Cancer: Zejula also received approval for the treatment of advanced ovarian cancer in patients who have received at least three prior chemotherapy regimens and have specific genetic mutations known as BRCA mutations. These mutations make cancer cells more susceptible to the effects of PARP inhibitors like Zejula.
  3. Advanced Breast Cancer: In certain cases, Zejula may be used to treat HER2-negative metastatic breast cancer in individuals who have received prior chemotherapy. This indication is usually for patients who have a BRCA mutation.

Please note that the approved indications for Zejula may have evolved since my last update, and it is crucial to consult the latest medical literature or a healthcare professional for the most current information.

Efficacy and Clinical Trials

The development and approval of Zejula were supported by rigorous clinical trials that demonstrated its efficacy and safety in cancer patients. These trials involved thousands of participants and provided valuable insights into the drug’s potential benefits.

In the NOVA trial, which focused on patients with recurrent ovarian cancer, Zejula showed a significant improvement in progression-free survival compared to a placebo. This means that patients who received Zejula experienced a longer period of time without their cancer progressing.

Similarly, in the QUADRA trial, Zejula exhibited promising results in women with advanced ovarian cancer who had received multiple lines of chemotherapy. The study showed that Zejula had a meaningful impact on disease control and overall survival in this challenging patient population.

Side Effects and Safety Profile

Like all medications, Zejula comes with a range of potential side effects. Common side effects of Zejula may include nausea, fatigue, constipation, abdominal pain, and anemia. It is essential for patients to discuss any side effects they experience with their healthcare provider, as there are strategies to manage these symptoms.

One notable aspect of Zejula’s safety profile is its potential to cause bone marrow suppression, which can result in low blood cell counts. Regular monitoring of blood counts is typically recommended during treatment to manage this risk.

Patients taking Zejula should also be aware of the potential for more severe side effects, such as hypertension (high blood pressure) and myelodysplastic syndrome (a disorder that affects blood cell production). These adverse events are relatively rare but require close monitoring by healthcare providers.

Patient Selection and Genetic Testing

One crucial factor in determining the suitability of Zejula treatment is genetic testing. Zejula is most effective in patients who have specific genetic mutations, particularly BRCA mutations. These mutations can make cancer cells more vulnerable to the effects of PARP inhibitors like Zejula.

Before starting Zejula, healthcare providers often recommend genetic testing to identify whether a patient has these mutations. This information helps guide treatment decisions and ensures that the drug is administered to those who are most likely to benefit from it.

Conclusion

Zejula, or Niraparib, represents a significant advancement in cancer treatment, offering new hope to patients with certain types of ovarian and breast cancer. Its mechanism of action, targeting DNA repair processes in cancer cells, has shown remarkable efficacy in clinical trials, leading to its approval for various indications. However, it is essential to recognize that Zejula is not a one-size-fits-all solution, and patient selection, including genetic testing, plays a critical role in determining its suitability.

While Zejula holds great promise, it is not without side effects, some of which can be severe. Close collaboration between patients and healthcare providers is vital to monitor and manage these side effects effectively.

As medical research continues to advance, Zejula exemplifies the progress made in the field of targeted cancer therapies. It stands as a beacon of hope for patients and a testament to the relentless pursuit of innovative treatments to improve the lives of those affected by cancer.

Package

56 capsules of 100 mg, 84 capsules of 100 mg

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Perjeta (Pertuzumab) Online

$2,491.01
(0 Reviews)
DISEASE INDICATIONS: Breast Cancer MANUFACTURER: Roche Registration Limited USAGE: Intravenous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Perjeta, also known by its generic name Pertuzumab, is a monoclonal antibody drug developed by Genentech, a member of the Roche Group. It was approved by the United States Food and Drug Administration (FDA) in 2012, marking a significant milestone in the treatment of HER2-positive breast cancer, a particularly aggressive and fast-growing form of the disease. Perjeta is often used in combination with other medications, most notably Herceptin (Trastuzumab), and chemotherapy agents like docetaxel.

Buy Tecentriq (Atezolizumab) Online

$6,105.91
(0 Reviews)
DISEASE INDICATIONS: Urothelial Carcinoma, Breast Cancer, Lung Cancer MANUFACTURER: Roche Registration Limited USAGE: Intravenous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Pharmaceuticals and Medical Devices Agency (PMDA) Therapeutic Goods Administration (TGA) Medsafe (NZ) It belongs to a class of drugs known as immune checkpoint inhibitors and has been approved for the treatment of multiple types of cancer.

Buy Lynparza (Olaparib) Online

$5,156.65
(0 Reviews)
DISEASE INDICATIONS: Breast Cancer, Gynaecological Cancer MANUFACTURER: AstraZeneca AB USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Lynparza, also known by its generic name Olaparib, represents a pivotal breakthrough in the field of oncology, specifically in the treatment of certain types of cancer, by harnessing the power of targeted therapy.

Buy Zejula (niraparib) Online

From $4,886.66
(0 Reviews)
DISEASE INDICATIONS: Gynaecological Cancer MANUFACTURER: Tesaro UK Limited USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Zejula is primarily indicated for the treatment of ovarian cancer and, in some cases, breast cancer.

Buy Rydapt (midostaurin) Online

$14,303.19
(0 Reviews)
DISEASE INDICATIONS: Leukemia MANUFACTURER: Novartis Europharm Limited USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Rydapt is a groundbreaking medication, primarily used in combination with standard chemotherapy for newly diagnosed AML patients who have a specific genetic mutation known as FLT3 mutation.

Buy Rubraca (rucaparib) Online

From $1,647.81
(0 Reviews)
DISEASE INDICATIONS: Gynaecological Cancer MANUFACTURER: Clovis Oncology, Inc. USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Rubraca is indicated for the treatment of women with advanced ovarian cancer who have received two or more prior lines of chemotherapy and have a deleterious BRCA mutation, as detected by an FDA-approved test.

Buy Portrazza (necitumumab) Online

$7,535.16
(0 Reviews)
DISEASE INDICATIONS: Lung Cancer MANUFACTURER: Eli Lilly Nederland B.V. USAGE: Intravenous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Portrazza, with its generic name Necitumumab, is a monoclonal antibody developed by Eli Lilly and Company. It received approval from the United States Food and Drug Administration (FDA) in late 2015, marking a significant advancement in the treatment of advanced squamous NSCLC.

Back to Top
Product has been added to your cart